Summary Loss of DNA mismatch repair is a common finding in hereditary non-polyposis colon cancer as well as in many types of sporadic human tumours. We compared the effect of loss of DNA mismatch repair on drug sensitivity as measured by a clonogenic assay with its effect on the ability of the same drug to enrich for mismatch repair-deficient cells in a proliferating tumour cell population. Mixed populations containing 50% DNA mismatch repair-deficient cells constitutively expressing green fluorescent protein and 50% mismatch repair-proficient cells were exposed to different chemotherapeutic agents. 6-Thioguanine, to which DNA mismatch repair-deficient cells are known to be resistant, was included as a control. The results in the cytotoxicity assays and in the enrichment experiments were concordant. Treatment with either carboplatin, cisplatin, doxorubicin, etoposide or 6-thioguanine resulted in enrichment for mismatch repair-deficient cells, and clonogenic assays demonstrated resistance to these agents, which varied from 1.3-to 4.8-fold. Treatment with melphalan, paclitaxel, perfosfamide or tamoxifen failed to enrich for mismatch repair-deficient cells, and no change in sensitivity to these agents was detected in the clonogenic assays. These results identify the topoisomerase 11 inhibitors etoposide and doxorubicin as additional agents for which loss of DNA mismatch repair causes drug resistance. The concordance of the results from the two assay systems validates the enrichment assay as a rapid and reliable method for screening for the effect of loss of DNA mismatch repair on sensitivity to additional drugs.
The DNA mismatch repair system plays an important role in the maintenance of genomic stability as it corrects replicative mismatches that escape DNA polymerase proofreading. Biochemical and genetic studies in eukaryotes have defined at least five genes, MSH2, MSH3, MSH6 (also called GTBP), MLHI and PMS2, whose protein products are required for eukaryotic mismatch repair (reviewed by Kolodner, 1996) . MSH2, dimerized with either MSH6 (Palombo et al, 1995) or MSH3 (Acharya et al, 1996) , binds to the mismatch and subsequently recruits the other mismatch repair proteins. Loss of DNA mismatch repair is the genetic basis for the hereditary non-polyposis colon cancer syndrome and is a common finding in a variety of sporadic cancers (reviewed by Fishel et al, 1995) . In addition to being involved in oncogenesis, loss of the DNA mismatch repair activity is of concern with respect to the use of chemotherapeutic agents to treat established tumours. Loss of mismatch repair has been reported to cause high-level resistance to the antimetabolite 6-thioguanine (Griffin et al, 1994) , moderate levels of resistance to the methylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (Kat et al., 1993) and temozolomide (Liu et al, 1996) , and low-level resistance to cisplatin and carboplatin Fink et al, 1996) in human tumour cell lines in vitro. In addition to intrinsic resistance to these agents, DNA mismatch repairdeficient cells have high mutation rates in both non-coding microsatellite sequences and in coding sequences of a number of genes including the HPRT (Bhattacharyya et al, 1994) , TGF-f2 (Markowitz et al, 1995) , and APC (Huang et al, 1996) genes.
If loss of DNA mismatch repair reduces tumour cell sensitivity, then one would expect treatment with chemotherapeutic agents to enrich tumour cell populations for mismatch repair-deficient cells. However, no information is available on how these parameters are linked quantitatively. To investigate this issue, we examined the ability of chemotherapeutic agents to enrich for mismatch repairdeficient cells during treatment and compared these results with the effect of loss of DNA mismatch repair on sensitivity to the same agents tested in clonogenic assays. In addition to cisplatin and carboplatin, we identified the topoisomerase II inhibitors etoposide and doxorubicin as chemotherapeutic agents that enrich for mismatch repair-deficient cells. Furthermore, our results validate the enrichment assay as a quick and reliable method for screening for changes in drug sensitivity mediated by loss of DNA mismatch repair.
MATERIALS AND METHODS Cell lines
The hMLH1-deficient human colorectal adenocarcinoma cell line HCT 1 16 was obtained from the American Type Culture Collection (ATCC CCL 247); sublines complemented with chromosome 2 (clone HCT116/2-1, identified here as HCT116 + ch2) and with chromosome 3 (clone HCT116/3-6, identified here as HCTl 16 + ch3) were obtained from Drs CR Boland and TA Kunkel (Koi et al, 1994) . Parental HCTl 16 cells are DNA mismatch repair-deficient as a result of a hemizygous mutation in hMLHI resulting in a truncated, non-functional protein (Boyer et al, 1995 Enrichment of DNA mismatch repair-deficient cells 705 (Crameri et al, 1996; Naviaux et al, 1996) . Amphotropic retrovirus was produced by co-transfecting 2 x 106 late-passage 293 cells with 20 ,ug of vector, either pCLNCX or pCLNCGFP, and the pCL-Ampho packaging-vector as described by Naviaux et al (1996) . Viral supermatant was harvested 24 and 48 h after transfection. Viral titres were determined on BALB/c 3T3 cells by geneticin-resistant colony formation. HCT1 16 cells were infected with viral supematant three times over a 12-h period in the presence of polybrene (8 ,ug ml-'). Infected cells were selected for 9 days with geneticin (400 jg ml-') and the resulting population was identified as HCT1 16-GFP; GFP was expressed in high levels in 90-95% of these cells. 
RESULTS

Cytotoxicity assays
The DNA mismatch repair-deficient HCT1 16 + ch2 cell line is known to be resistant to 6-thioguanine (Griffin et al, 1994) , MNNG (Kat et al, 1993) and cisplatin and carboplatin Fink et al, 1996) . Figure 1 
Enrichment assays
Parental DNA mismatch repair-deficient HCT116 cells were infected with a retrovirus encoding the GFP gene driven by a CMV promoter, and a population that stably expressed GFP was selected. A population containing 50% DNA mismatch repairdeficient GFP-expressing cells and 50% repair-proficient HCT1 16 + ch3 cells was prepared by mixing and subjected to drug exposure. Five days later, the population was analysed by flow cytometry to document the proportion of GFP-expressing mismatch repair-deficient cells. Table 2 demonstrates the effect of loss of DNA mismatch repair on enrichment after a 1-h drug exposure (cisplatin, carboplatin), a 24-h drug exposure (etoposide, melphalan, paclitaxel, perfosfamide, 6-thioguanine), or a continuous drug exposure (doxorubicin, tamoxifen). Five days after a single exposure to an IC 50 concentration of etoposide, the treated population contained 44% more GFP-expressing mismatch repairdeficient cells than the untreated population. Likewise, the tumour cell population contained 36% more mismatch repair-deficient cells after a single exposure to doxorubicin. Thus, treatment with doxorubicin or etoposide, to which the DNA mismatch repairdeficient cells were twofold resistant, resulted in rapid enrichment of the population for the resistant cells.
DISCUSSION
Loss of DNA mismatch repair can impact on the responsiveness of a tumour to chemotherapy in several different ways. First, loss of mismatch repair produces high-level resistance to the antimetabolite 6-thioguanine (Griffin et al, 1994) , moderate levels of resistance to the methylating agent MNNG (Kat et al, 1993 ) and low-level resistance to cisplatin and carboplatin Fink et al, 1996) . It has recently been reported that loss of mismatch repair also causes resistance to temozolomide, a methylating agent that forms adducts similar to those of MNNG (Liu et al, 1996) . Second, the genomic instability that accompanies loss of DNA mismatch repair can increase the rate of mutation in the coding or regulatory sequences of other genes whose products may play central roles in determining tumour cell sensitivity to drugs. It has been suggested that the DNA mismatch repair system serves as a detector for the presence of DNA damage (Kat et al, 1993; Hawn et al, 1995) . Resistance to 6-thioguanine, MNNG, temozolomide, cisplatin and carboplatin is thought to result from failure of the cell to recognize the DNA adducts formed by these drugs and to activate signalling pathways that trigger apoptosis. Indeed, pure hMSH2 has been reported to bind to platinated DNA in mobility shift assays (Mello et al, 1996) , and human MutSa (Duckett et al, 1996) , a heterodimer of hMSH2 and hMSH6 (Palombo et al, 1994; Acharya et al, 1996) , has been shown to bind to DNA containing adducts produced by MNNG, 6-thioguanine and cisplatin. The molecular basis for the concept that-loss of DNA mismatch repair causes resistance rather than hypersensitivity because the mismatch repair proteins serve as a detector of damage has been further substantiated by the recent observation that loss of mismatch repair results in failure to activate several cisplatin damage-responsive signal transduction pathways (Nehme et al, 1997) . In contrast, loss of mismatch repair does not result in resistance to oxaliplatin, and although little is known about the oxaliplatin adduct (Woynarowski et al, 1997) , we have recently demonstrated that DNA adducts formed by oxaliplatin are not recognized by the mismatch repair system .
The results of both the cytotoxicity assays and enrichment assays reported here provide additional confirmation that loss of mismatch repair results in resistance to 6-thioguanine, cisplatin and carboplatin. As loss of DNA mismatch repair is not accompanied by resistance to the classical alkylating agents melphalan and perfosfamide, it is likely that the adducts produced by these agents are not recognized by the mismatch repair detector. Similarly, it has been reported that the adducts formed by the chloroethylating agent 1,3-bis(2-chloroethyl)-nitrosourea are not recognized by the mismatch repair complex (Liu et al, 1996) . The lack of differential cytotoxicity of paclitaxel and tamoxifen is consistent with the fact that neither agent is known to interact with DNA at achievable clinical concentrations.
The results presented here extend the panel of drugs for which loss of mismatch repair causes resistance to the topoisomerase II inhibitors etoposide and doxorubicin. However, how loss of DNA mismatch repair produces low-level resistance to these agents is less clear than for those agents that react directly with DNA to produce adducts that distort its structure in a manner similar to that of true DNA mismatches. It may be that the mismatch repair proteins serve as a detector of the 'cleavable complex' (Chen et al, 1994) produced by the binding of etoposide or doxorubicin to topoisomerase I1, or that the mismatch repair proteins normally act to stabilize the drug-induced 'cleavable complex' on the DNA, and thus serve to augment the DNA damage. Additional studies will be required to document interaction between the DNA mismatch repair proteins and topoisomerase II.
Several lines of evidence suggest that although loss of mismatch repair results in only relatively small degrees of resistance, this resistance is nevertheless of biological and clinical significance. First, even a twofold difference in sensitivity to cisplatin, carboplatin, doxorubicin and etoposide detected by clonogenic assays was sufficient to result in a clear enrichment for mismatch repairdeficient cells after only a single exposure of a proliferating tumour cell population to these drugs. Second, loss of DNA mismatch repair has been reported in tumour cell lines selected for resistance to cisplatin or doxorubicin . Third, this laboratory has previously documented that only small degrees of resistance (< twofold) are required to account for clinical failure of cisplatin treatment (Andrews et al, 1990) . MSH2+'+ embryonic stem cells (de Wind et al, 1995) grown as xenografts were responsive to treatment with a single LD1O dose of cisplatin, whereas isogenic MSH2-'-tumours were not, suggesting that the degree of cisplatin resistance conferred by loss of DNA mismatch repair is sufficient to produce a large difference in clinical responsiveness in vivo (Fink et al, British Journal of Cancer (1998) 77(5), [703] [704] [705] [706] [707] [708] Enrichment of DNA mismatch repair-deficient cells 707 1997). Because of the fact that embryonic stem cells require a drug-sensitive fibroblast feeder layer for prolonged propagation, studies of the extent to which low-level resistance can mediate enrichment for mismatch repair-deficient cells during treatment in vitro could not be addressed in this isogenic system, and we were limited to using the less truly isogenic HCTI 16 and HCT1 16 + ch3 pair of cells. Nevertheless, our results argue cogently that treatment with any of these five agents (carboplatin, cisplatin, doxorubicin, etoposide, 6-thioguanine) does select for repair-deficient cells, thus enriching the population. Additional studies are required to further document the kinetics of this process and the extent of enrichment that occurs in vivo with repeated cycles of drug exposure. However, it is likely that clinical resistance will become manifest at relatively low levels of enrichment. In mixing experiments performed with L1210 leukaemia cells sensitive and resistant to cyclophosphamide, Skipper et al (1978) demonstrated that the presence of only 1% resistant cells was sufficient to cause clinical failure of treatment.
The issue of when loss of mismatch repair occurs during oncogenesis remains controversial, even for hereditary non-polyposis colon cancer, which represents the best defined clinical situation (Tomlinson et al, 1996) . However, once such cells are present in the tumour, their genomic instability may result in the accumulation of additional mutations that contribute to the phenomenon of tumour progression. Enrichment of these cells as a result of chemotherapy would be expected to accelerate this process. Indeed, Ben-Yehuda et al (1996) recently reported that microsatellite instability, a hallmark of the genomic instability due to the loss of mismatch repair (Loeb et al, 1994) , was present in up to 94% of the patients with therapy-related leukaemia or myelodysplastic syndromes, consistent with drug-induced enrichment for genetically unstable cells.
The perfect concordance between the ability of a drug to enrich for GFP-expressing mismatch repair-deficient cells and loss of sensitivity to the same drug as assessed by clonogenic assay suggests that the former can be used as a way of rapidly screening for DNA mismatch repair-mediated changes in sensitivity to additional agents. The assay can be readily automated for high throughput screening, and the same principle can be used to examine the impact of the loss of other genes when isogenic pairs of cell lines are available.
